医药行业周报：赛诺菲Lunsekimig在华获批临床，用于治疗哮喘

Investment Rating - The report does not provide specific ratings for the chemical pharmaceuticals and traditional Chinese medicine sectors, while the biopharmaceutical sector is rated as Neutral [2][10]. Core Insights - The pharmaceutical sector experienced a decline of 2.95% on November 14, 2024, underperforming the CSI 300 index by 1.22 percentage points, ranking 22nd among 31 sub-industries in the Shenwan classification [4]. - Among sub-industries, blood products (-2.32%), pharmaceutical distribution (-2.61%), and in vitro diagnostics (-2.83%) performed relatively better, while hospitals (-4.33%), vaccines (-3.87%), and medical research outsourcing (-3.85%) lagged behind [4]. - Notable stock performances included Weier Pharmaceutical (+7.04%), Chengda Pharmaceutical (+5.35%), and Guangji Pharmaceutical (+5.31%) on the gainers' list, while Weikang Pharmaceutical (-11.13%), Toukeng Life (-9.88%), and Yaoyigou (-9.78%) were among the biggest losers [4]. Summary by Sections Industry News - Sanofi's new drug Lunsekimig has received clinical trial approval in China for treating high-risk asthma in adults. This drug targets IL-13 and TSLP and has previously been granted IND approval in China for moderate to severe asthma [5]. - Haizheng Pharmaceutical announced that its subsidiary received approval for new veterinary drug products, enhancing its product line and market competitiveness [5]. - Heng Rui Pharmaceutical's subsidiary has received clinical trial approval for HRS-5632 injection, aimed at treating lipoprotein disorders [5]. - Oriental Bio's subsidiary has obtained CLIA certification for its COVID-19 antigen test kit, expanding its product offerings in the U.S. and Canada [5]. - Chengda Pharmaceutical has received approval for the active pharmaceutical ingredient Dapagliflozin, further diversifying its product line [5].